Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
Trial Parameters
Brief Summary
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
Eligibility Criteria
Inclusion Criteria: * Subject must be age ≥18 years; * Subject has mPAP 21-24 mmHg, and PAWP\<15mmHg.The underlying diseases that cause critical PAH belong to the first group, which is divided into: Idiopathic pulmonary hypertension, hereditary pulmonary hypertension, drugs and poisons associated with pulmonary hypertension, connective tissue diseases associated with pulmonary hypertension, HIV infection associated with pulmonary hypertension, portal hypertension associated with pulmonary hypertension, tumors associated with pulmonary hypertension, congenital heart disease associated with pulmonary hypertension. * Subject (or legal guardian) understands the trial design and treatment procedures and provides written informal consent before any trial-specific tests or procedures are performed. Exclusion Criteria: * Pulmonary hypertension (PH) confirmed by right heart catheter (RHC) before enrolment, i.e. mPAP ≥25 mmHg at rest. * Ongoing or a history of \>2 weeks of continued use of thera